AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00478803 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remodeling procedure associated with a subvalvular aortic ring or double sub and supra-valvular aortic annuloplasty
Description: Remodeling procedure associated with a subvalvular aortic ring: a) Five U stitches are placed inside out in the subvalvular plane (3 stitches 2 mm below the nadir of insertion of each cusp, 2 stitches below 2 of the 3 commissures at the base of the interleaflet triangles (no suture is placed at the base of the interleaflet triangle situated between the right and noncoronary sinuses to avoid injury of the bundle of His)); b) remodeling of the aortic root by scalloping a bulged graft (Gelweave ValsalvaTM); c) The 5 anchoring U stitches are passed through the inner aspect of the prosthetic aortic ring and tied down externally in the subvalvular position; d) anastomosis of the coronary ostia and to distal ascending aorta.
Study NCT00478803 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Mechanical valve replacement (isolated or composite valve and graft replacement); actual surgical standard for dystrophic aortic roots
Description: Expansible Prosthetic Aortic Ring: Mechanical valve replacement (isolated or composite valve and graft replacement); actual surgical standard for dystrophic aortic roots
Study NCT01455532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iniparib (SAR240550-BSI-201)
Description: Pharmaceutical form:Solution for infusion~Route of administration: Intravenous
Study NCT01455532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Pharmaceutical form:Solution for infusion~Route of administration: Intravenous
Study NCT01455532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Pharmaceutical form:Solution for infusion~Route of administration: Intravenous
Study NCT01455532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placlitaxel
Description: Pharmaceutical form:Solution for infusion~Route of administration: Intravenous
Study NCT01455532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin
Description: Pharmaceutical form:Solution for infusion~Route of administration: Intravenous
Study NCT01814696 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MedSentry System
Description: Subjects will use the MedSentry System and electronic pillbox, to manage their medications.
Study NCT02995174 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dichoptic video game in an i-Pod touch device
Description: Amblyope will wear a pair of red green goggles and play the video game with 'contrast-balanced' images displayed on the screen of an i-Pod touch device. The eye with weaker eyesight will see the image with high contrast, and the good eye will see the image with low contrast. The subject will play the game one hour per day for 6 weeks.
Study NCT02995174 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Video game in an i-Pod touch device
Description: Amblyope will wear a pair of red green goggles and play the video game with equal contrast images displayed on the screen of an i-Pod touch device. Both eyes will see the image of same contrast. The subject will play the game one hour per day for 6 weeks.
Study NCT04736277 — intervention group
Intervention type: OTHER
Intervention: Preoperative HbA1c
Description: Documentation of the preopetative HbA1c in patients undergoing noncardiac surgery under general anesthesia
Study NCT03508726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbate
Description: Phase 1 dose escalation:~75gm IV three times a week~Phase II portion:~75gm IV three times a week if no dose limiting toxicities are experienced in the Phase I portion. Otherwise, ascorbate dose will be deescalated to 62.5 gm IV
Study NCT04010747 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Interviewing for Loved Ones (MILO)
Description: 4 sessions of behavioral coaching in motivational interviewing communication techniques
Study NCT04010747 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing for Loved Ones (MILO)
Description: 4 sessions of behavioral coaching in motivational interviewing communication techniques
Study NCT04010747 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mental Health Services Consultation and Waitlist
Description: 1 session of individualized consultation on relevant mental health services for the IP and participating PCSO and 6 weeks on a waitlist, followed by opportunity to participate in MILO sessions.
Study NCT03928899 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: New procedure
Description: An optimal management on the timing and mode of delivery of pregnant women with GDM, by a comprehensive assessment and consideration of their fetal weight, gestational age, and cervical ripeness.
Study NCT00650247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sumatriptan Succinate Tablets 100 mg
Description: 100mg, single dose fed
Study NCT00650247 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imitrex® Tablets 100 mg
Description: 100mg, single dose fed
Study NCT00030667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: Given orally
Study NCT00030667 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00030667 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT02647723 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DHA
Description: 2 dietary supplement gel capsules providing 450 mg of DHA twice daily by oral intake for 24 weeks
Study NCT02647723 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Description: 2 dietary supplement gel capsules providing 450 mg of soybean oil twice daily by oral intake for 24 weeks
Study NCT04150796 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ventral Hernia Repair
Description: Participants will undergo robotic ventral hernia repair according to the assigned treatment arm.
Study NCT02883062 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV
Study NCT02883062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT02883062 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lumpectomy
Description: Undergo lumpectomy
Study NCT02883062 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumpectomy
Description: Undergo lumpectomy
Study NCT02883062 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mastectomy
Description: Undergo mastectomy
Study NCT02883062 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mastectomy
Description: Undergo mastectomy
Study NCT02883062 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Given IV
Study NCT02883062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT02778100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nasal Glucagon
Description: Administered intranasally.
Study NCT02778100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxymetazoline
Description: Administered intranasally.
Study NCT03113474 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food palatability
Description: Food palatability is modulated
Study NCT02671448 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home monitoring teleconsult visits
Description: A tablet will be provided to both the patient and the caregiver during the homecare portion of the study. The tablet will remain at the home, to be used by the patient and the caregiver during daily homecare visits to complete instruments/surveys and video diary recording sessions.
Study NCT02671448 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Reported Outcomes (PRO)
Description: Distress Thermometer, MSK-Modified M.D. Anderson Symptom Inventory (MDASI) Instrument, FACT-G Instrument, FACT-BMT Instrument
Study NCT02671448 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caregiver Reported Outcomes instruments
Description: Distress Thermometer, Caregiver Reaction Assessment (CRA) Instrument, The Caregiver Quality of Life Index-Cancer (CQOLC) Scale, Satisfaction Questionnaire, Video Diary Entries
Study NCT00815282 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Human papilloma virus vaccine (cervarix)
Description: vaccination at 0, 1 and 6 months
Study NCT00671931 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: low dexmedetomidine, low propofol
Description: Dexmedetomidine loading dose 0.6 MCG/KG,Propofol infusion 100 MCG/KG/M
Study NCT00671931 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: high dexmedetomidine, low propofol
Description: Dexmedetomidine loading dose 1.1 MCG/KG ,Propofol infusion 100 MCG/KG/M
Study NCT00671931 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine loading dose 0.6 MCG/KG,Propofol infusion 200 MCG/KG/M
Study NCT00671931 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidin
Description: Dexmedetomidine loading dose 1.1 MCG/KG.Propofol infusion 200 MCG/KG/M
Study NCT00671931 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine loading dose 0.9 mcg/kg,Propofol infusion 140 mcg/kg/min
Study NCT01249248 — intervention group
Intervention type: DEVICE
Intervention: PD2i Analyzer
Description: Analysis of heart rate variability from a standard digital ECG for 6-12 minutes
Study NCT01975896 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation
Description: The intervention's curriculum will include: 1) the body scan; 2) training in the awareness of the sensations of breathing; 3) training in directing the attention to simple activities of daily life; 4) practice of 'open awareness' in which students will be instructed to just notice which events (physical sensation, sound, visual object, thought) their attention is spontaneously drawn to from moment to moment; 5) mindful movement (standing and walking exercises); and 6) mindful eating. In addition to the weekly training session, students will practice mindfulness techniques for 15 minutes daily in class with the health education teacher and for an additional 15 minutes daily on their own
Study NCT02507648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: 1 tablet contains 75 mg oseltamivir
Study NCT02507648 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamiflu®
Description: 1 tablet contains 75 mg oseltamivir
Study NCT05437081 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Latino Emerging Adults (LEA)
Description: The LEA program involves two components, one for emerging adults (aged 18-23 years old) focused on identity development linked to cultural and familial strengths, and a parent component focused on support for emerging adult children. Each session is 4 sessions.
Study NCT01169675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992 low dose
Description: patient receives low dose BIBW 2992 po daily on day 1 of 21 day cycle
Study NCT01169675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992 high dose
Description: patient receives high dose BIBW 2992 po daily on day 1 of 21 day cycle
Study NCT01169675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: given intravenously on day 1 of a 21 day cycle
Study NCT04150796 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ventral Hernia Repair
Description: Participants will undergo robotic ventral hernia repair according to the assigned treatment arm.
Study NCT01169675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992 high dose 6 day
Description: patient receives high dose BIBW 2992 po daily on days 1-6 on 1 of 21 day cycle
Study NCT01169675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992 low dose 6 day
Description: patient receives low dose BIBW 2992 po daily on days 1-6 on day 1 of 21 day cycle
Study NCT01082263 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lurasidone HCl
Description: Day1: 5 mg midazolam (2.5 mL of the 2 mg/mL syrup) Day6: 120 mg lurasidone (three 40 mg tablets) + 5 mg midazolam (2.5 mL of the 2 mg/mL syrup) Day 7-12: 120 mg lurasidone (three 40 mg tablets) 120 mg lurasidone (three 40 mg tablets) on Day 13 + 5 mg midazolam (2.5 mL of the 2 mg/mL syrup)
Study NCT03445546 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: diagnostic test of platelet function
Description: Light transmittance aggregometry and VerifyNow
Study NCT01194999 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pubovaginal sling procedure
Description: The procedure involves placing a band of sling material directly under the bladder neck (ie, proximal urethra) or mid-urethra, which acts as a physical support to prevent bladder neck and urethral descent during physical activity. The sling also may augment the resting urethral closure pressure with increases in intra-abdominal pressure.
Study NCT02001844 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trial Foot Orthoses (FOs)
Description: Trial Group:~The children who were randomly introduced into this group received the pre-formed semi-rigid FOs. The FOs were used as an off the-shelf device and subsequently customised with chair side modifications. In order to reproduce the exact same aesthetical appearance as the control FOs, grey poron (1mm) and black EVA (0.75mm) was used as well to cover the trial FOs.~Furthermore, depending on the type of correction applied to the trial patient, the black EVA also allowed the correction applied on the surface of the device to be masked.
Study NCT02001844 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: placebo foot orthoses (FOs)
Description: The control FOs, or placebo FOs was supplied to patients who were randomly included in the control group. The control FOs was made of leather board (1mm), grey Poron (1mm), and black EVA (0.75mm) as covering. This thin inner sole did not have any sort of biomechanical support, nor had it any effect on the distribution of pressure, as it was completely flat. In addition, the placebo FOs did not present with any intrinsic or extrinsic correction underneath the sub-talar-joint (STJ).~The use of black EVA as the covering material and the leather-board as a base, allowed for gathering of a dynamic impression over the 6 months of the trial.
Study NCT04927832 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SUDOSCAN and EMG (electromyogram)
Description: The participants are evaluated clinically by a neurologist with evaluation by DN4 questionnaire, treatments and comorbidities (alcohol consumption, diabetes, etc.). They undergo from exploration by SUDOSCAN according to the already established methodology and an EMG
Study NCT01169675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992 medium dose 6 day
Description: patient receives medium dose BIBW 2992 po daily on day1 to 6 of a 21 day cycle
Study NCT01169675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992 medium dose
Description: patient receives medium dose BIBW 2992 po daily on day 1 of 21 day cycle
Study NCT00445679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DVS SR
Description: Arm 1: 50mg DVS SR tablet, QD, 8 weeks treatment with 2 week taper Arm 2: 100mg DVS SR tablet, QD, 8 weeks treatment with 2 week taper Arm 3: 200mg DVS SR tablet, QD, 8 weeks treatment with 2 week taper
Study NCT00445679 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paroxetine
Description: 20 mg Paroxetine capsule, QD, 8 weeks treatment with 2 week taper
Study NCT04445480 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Popliteal block
Description: Sciatic nerve block at popliteal fossa would perform before the participant undergoing angioplasty in experimental arm.
Study NCT04445480 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Sciatic nerve at popliteal fossa would be scanned with the ultrasound. The toothpick would be applied to simulate the procedure of nerve block.
Study NCT03375983 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood-stage infection of P.vivax
Description: The P. vivax infected blood will be confirmed to follow the national standard of blood donation to ensure that only P. vivax is included, excluding the presence of P. falciparum. Exclude other infectious diseases according to the test of national standard of blood donation.
Study NCT03815877 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nescafe Gold ® coffee
Description: Nescafe Gold ® coffee (5gm per 100cc water containing 170 mg of caffeine) will be used for all the women in the intervention group.~- patients will drink 100cc coffee with 1 tea spoon added sugar at 3, 6 and 9 hours after the surgery.
Study NCT03815877 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Nescafe Gold DECAF® coffee
Description: Nescafe Gold DECAF coffee (5 gm per 100cc water containing 5-10 mg of caffeine) will be used for all the women in the control group.~the control group will drink 100cc decaffeinated coffee with 1 tea spoon added sugar at 3, 6 and 9 hours after the surgery.
Study NCT00707681 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MS-20
Description: 4 ml/vial
Study NCT00707681 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4ml/vial
Study NCT02146196 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 4 weeks robotic assisted training with the Lokomat®
Description: During a prespecified time period (4weeks) a three times weekly robotic assisted gait training during 30-45 minutes. Strength training, interval training and endurance training are possible.
Study NCT02146196 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: One week robotic assisted gait training with the Lokomat®
Description: During a prespecified time period (1week) a three times weekly robotic assisted gait training during 10-40 minutes. Strength training, interval training and endurance training are possible
Study NCT05736640 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Denosumab
Study NCT05736640 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01738503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBP-6000
Description: 18% Buprenorphine Sterile Solution for subcutaneous (SC) injection using the ATRIGEL® Delivery System. Each injection of RBP-6000 is separated by a minimum of 28 days and given on alternate sides of the participant's abdomen.
Study NCT01738503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subutex
Description: Participants were inducted and stabilized over a 14-day period (study days -14 to -1) on SUBUTEX sublingual tablets. Tablets are placed under the tongue until dissolved.
Study NCT03762863 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tourniquet application skill retention
Description: Tourniquet application following the procedure as learned in the Stop the Bleed curriculum.
Study NCT03688178 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human CMV pp65-LAMP mRNA-pulsed autologous DCs
Description: 2x10\^7 human CMV pp65-LAMP mRNA-pulsed autologous DCs are given intradermally and bilaterally at the groin site (divided equally to both inguinal regions). Patients will receive up to a total of 10 DC vaccines.
Study NCT03688178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide is a standard chemotherapy given to all enrolled patients at a targeted dose of 150-200mg/m2/d for 5 days every 4 (+ 2) weeks for up to 12 cycles (patients with unmethylated MGMT gene promoter will receive only cycle 1)
Study NCT03688178 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Varlilumab
Description: Varlilumab is an agonist anti-CD27 monoclonal antibody
Study NCT03688178 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Td
Description: A single dose of Td toxoid (1 flocculation unit, Lf, in 0.4 mLs) administered to a single side of the groin given intradermally
Study NCT00679523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AN2690 Solution, 7.5%
Description: Once daily application for 180 days
Study NCT03931083 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Screening for CIN2+/HSIL
Description: The investigators will compare three different screening methods: visual assessment with portable magnification device , visual inspection after application of acetic acid, screening for high risk variants of HPV. All patients will receive cervical biopsies and histopathological examination.
Study NCT04381884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVERMECTIN (IVER P®) arm will receive IVM 600 µg / kg once daily plus standard care. CONTROL arm will receive standard care.
Description: IVERMECTIN (IVER P®) arm will receive IVM 600 µg / kg once daily plus standard care. CONTROL arm will receive standard care.
Study NCT03752593 — intervention group
Intervention type: OTHER
Intervention: ET Tube
Description: Patients with a BMI of greater than 30 or less than who are presenting to the hospital for any surgical procedure requiring general anesthesia
Study NCT00185419 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Yasmin
Description: 30 µg ethinylestradiol, 3mg drospirenone
Study NCT00185419 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Marvelon
Description: 30 µg ethinylestradiol, 150 µg desogestrel